vs
AtriCure, Inc.（ATRC）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是AtriCure, Inc.的1.3倍（$188.3M vs $140.5M），AtriCure, Inc.同比增速更快（13.1% vs -21.9%），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs -15.4%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
ATRC vs RILY — 直观对比
营收规模更大
RILY
是对方的1.3倍
$140.5M
营收增速更快
ATRC
高出34.9%
-21.9%
两年增速更快
ATRC
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $188.3M |
| 净利润 | — | $90.3M |
| 毛利率 | 75.0% | 79.5% |
| 营业利润率 | 1.8% | 32.3% |
| 净利率 | — | 47.9% |
| 营收同比 | 13.1% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.04 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCRILY
| Q4 25 | $140.5M | $188.3M | ||
| Q3 25 | $134.3M | $215.3M | ||
| Q2 25 | $136.1M | $188.2M | ||
| Q1 25 | $123.6M | $197.2M | ||
| Q4 24 | $124.3M | $241.0M | ||
| Q3 24 | $115.9M | $225.5M | ||
| Q2 24 | $116.3M | $256.0M | ||
| Q1 24 | $108.9M | $263.4M |
净利润ATRCRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-267.0K | $91.1M | ||
| Q2 25 | $-6.2M | $139.5M | ||
| Q1 25 | $-6.7M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-7.9M | $-284.4M | ||
| Q2 24 | $-8.0M | $-433.6M | ||
| Q1 24 | $-13.3M | $-49.2M |
毛利率ATRCRILY
| Q4 25 | 75.0% | 79.5% | ||
| Q3 25 | 75.5% | 83.7% | ||
| Q2 25 | 74.5% | 81.3% | ||
| Q1 25 | 74.9% | 81.4% | ||
| Q4 24 | 74.5% | 79.8% | ||
| Q3 24 | 74.9% | 82.1% | ||
| Q2 24 | 74.7% | 84.5% | ||
| Q1 24 | 74.7% | 85.3% |
营业利润率ATRCRILY
| Q4 25 | 1.8% | 32.3% | ||
| Q3 25 | 0.2% | 30.4% | ||
| Q2 25 | -4.5% | 5.7% | ||
| Q1 25 | -4.8% | -31.2% | ||
| Q4 24 | -11.7% | -69.2% | ||
| Q3 24 | -6.4% | -36.4% | ||
| Q2 24 | -6.2% | -90.8% | ||
| Q1 24 | -10.0% | -6.1% |
净利率ATRCRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | -0.2% | 42.3% | ||
| Q2 25 | -4.5% | 74.1% | ||
| Q1 25 | -5.5% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -6.8% | -126.1% | ||
| Q2 24 | -6.9% | -169.4% | ||
| Q1 24 | -12.2% | -18.7% |
每股收益（稀释后）ATRCRILY
| Q4 25 | $0.04 | $2.78 | ||
| Q3 25 | $-0.01 | $2.91 | ||
| Q2 25 | $-0.13 | $4.50 | ||
| Q1 25 | $-0.14 | $-0.39 | ||
| Q4 24 | $-0.33 | $-0.01 | ||
| Q3 24 | $-0.17 | $-9.39 | ||
| Q2 24 | $-0.17 | $-14.35 | ||
| Q1 24 | $-0.28 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $491.9M | $-171.5M |
| 总资产 | $654.2M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCRILY
| Q4 25 | $167.4M | $226.6M | ||
| Q3 25 | $147.9M | $184.2M | ||
| Q2 25 | $117.8M | $267.4M | ||
| Q1 25 | $99.9M | $138.3M | ||
| Q4 24 | $122.7M | $146.9M | ||
| Q3 24 | $130.3M | $159.2M | ||
| Q2 24 | $114.0M | $236.9M | ||
| Q1 24 | $106.0M | $190.7M |
总债务ATRCRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | $61.9M | $1.3B | ||
| Q2 25 | $61.9M | $1.3B | ||
| Q1 25 | $61.9M | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
股东权益ATRCRILY
| Q4 25 | $491.9M | $-171.5M | ||
| Q3 25 | $476.5M | $-260.5M | ||
| Q2 25 | $464.5M | $-351.7M | ||
| Q1 25 | $454.6M | $-496.8M | ||
| Q4 24 | $461.0M | $-488.2M | ||
| Q3 24 | $465.0M | $-497.6M | ||
| Q2 24 | $462.1M | $-218.3M | ||
| Q1 24 | $456.3M | $228.4M |
总资产ATRCRILY
| Q4 25 | $654.2M | $1.7B | ||
| Q3 25 | $635.4M | $1.7B | ||
| Q2 25 | $608.8M | $1.5B | ||
| Q1 25 | $591.6M | $1.5B | ||
| Q4 24 | $609.3M | $1.8B | ||
| Q3 24 | $615.1M | $2.2B | ||
| Q2 24 | $597.3M | $3.2B | ||
| Q1 24 | $591.6M | $5.0B |
负债/权益比ATRCRILY
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | — |
| 自由现金流率自由现金流/营收 | 13.1% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $48.3M | — |
8季度趋势，按日历期对齐
经营现金流ATRCRILY
| Q4 25 | $20.0M | $26.2M | ||
| Q3 25 | $26.7M | $-60.6M | ||
| Q2 25 | $21.6M | $-25.6M | ||
| Q1 25 | $-11.0M | $184.0K | ||
| Q4 24 | $5.8M | $-2.7M | ||
| Q3 24 | $20.0M | $19.5M | ||
| Q2 24 | $7.4M | $111.5M | ||
| Q1 24 | $-21.0M | $135.4M |
自由现金流ATRCRILY
| Q4 25 | $18.4M | — | ||
| Q3 25 | $24.1M | — | ||
| Q2 25 | $19.0M | — | ||
| Q1 25 | $-13.2M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $16.4M | — | ||
| Q2 24 | $5.0M | — | ||
| Q1 24 | $-23.8M | — |
自由现金流率ATRCRILY
| Q4 25 | 13.1% | — | ||
| Q3 25 | 18.0% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | -10.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | -21.9% | — |
资本支出强度ATRCRILY
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 2.5% | — |
现金转化率ATRCRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
